炎症性肠病治疗的新靶点：2021 年。
New targets in inflammatory bowel disease therapy: 2021.
机构信息
The University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
出版信息
Curr Opin Gastroenterol. 2021 Jul 1;37(4):357-363. doi: 10.1097/MOG.0000000000000740.
Abstract
PURPOSE OF REVIEW
In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD).
RECENT FINDINGS
Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn's disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies.
SUMMARY
The IBD physicians' therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care.
摘要
目的综述
在炎症性肠病快速发展的世界中，本综述讨论和总结了新药靶点和主要临床试验结果，以便为治疗炎症性肠病（IBD）患者的医生提供最新信息。
最近的发现
正在开发治疗 IBD 的多种新机制，其中许多在溃疡性结肠炎和克罗恩病患者中均显示出有前景的结果。除了疗效外，这些治疗方法中的一些可能比现有疗法具有更好的安全性。
总结
IBD 医生的治疗手段正在迅速扩展，为了为患者提供最佳的个体化护理，需要了解这些新进展。
相似文献
1
New targets in inflammatory bowel disease therapy: 2021.炎症性肠病治疗的新靶点：2021 年。
Curr Opin Gastroenterol. 2021 Jul 1;37(4):357-363. doi: 10.1097/MOG.0000000000000740.
2
Review of Saccharomyces boulardii as a treatment option in IBD.布拉氏酵母菌在炎症性肠病治疗中的应用评价。
Immunopharmacol Immunotoxicol. 2018 Dec;40(6):465-475. doi: 10.1080/08923973.2018.1469143. Epub 2018 May 17.
3
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.英夫利昔单抗与维得利珠单抗治疗炎症性肠病患者的疗效和安全性比较：系统评价和荟萃分析。
BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1.
4
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
5
Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).炎症性肠病专家对克罗恩病和溃疡性结肠炎新疗法定位的认知与临床决策：巴西炎症性肠病研究组（GEDIIB）开展的一项基于网络的全国性调查
Gastroenterol Hepatol. 2022 Aug-Sep;45(7):499-506. doi: 10.1016/j.gastrohep.2021.09.005. Epub 2021 Oct 8.
6
Use of antibiotics in the treatment of inflammatory bowel disease.抗生素在炎症性肠病治疗中的应用。
Inflamm Bowel Dis. 2006 Jul;12(7):651-64. doi: 10.1097/01.MIB.0000225330.38119.c7.
7
Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.生物疗法和小分子药物对炎症性肠病患者主要不良心血管事件风险的影响：随机对照试验的系统评价和荟萃分析
Expert Rev Gastroenterol Hepatol. 2023 May;17(5):469-477. doi: 10.1080/17474124.2023.2194631. Epub 2023 Apr 10.
8
Review article: emerging drug therapies in inflammatory bowel disease.综述文章：炎症性肠病的新兴药物治疗。
Aliment Pharmacol Ther. 2022 Apr;55(7):789-804. doi: 10.1111/apt.16785. Epub 2022 Feb 15.
9
Controlling in and out - the future of interfering with immune cell trafficking in inflammatory bowel disease.控制进出——炎症性肠病中干扰免疫细胞运输的未来。
Expert Rev Clin Immunol. 2023 Feb;19(2):155-167. doi: 10.1080/1744666X.2023.2152794. Epub 2022 Dec 5.
10
The treatment of inflammatory bowel disease with monoclonal antibodies in Asia.亚洲地区使用单克隆抗体治疗炎症性肠病的情况。
Biomed Pharmacother. 2023 Jan;157:114081. doi: 10.1016/j.biopha.2022.114081. Epub 2022 Dec 5.
引用本文的文献
1
Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study.一项关于石榴汁干预12周对炎症性肠病患者转录反应及降低粪便钙卫蛋白水平的调节作用的证据：一项原理验证研究的结果
Mol Nutr Food Res. 2025 Aug;69(15):e70067. doi: 10.1002/mnfr.70067. Epub 2025 Apr 21.
2
The Inflammatory Bowel Disease Knowledge Inventory Device 2 (IBD-KID2) is an effective tool for measuring disease-specific knowledge in Chinese patients.炎症性肠病知识量表2（IBD-KID2）是一种用于测量中国患者疾病特异性知识的有效工具。
PLoS One. 2025 Apr 1;20(4):e0321036. doi: 10.1371/journal.pone.0321036. eCollection 2025.
3
Gender Differences in Coping Strategies and Life Satisfaction Following Cognitive-Behavioral and Mindfulness-Based Intervention for Crohn's Disease: A Randomized Controlled Trial.针对克罗恩病的认知行为和正念干预后应对策略及生活满意度的性别差异：一项随机对照试验
J Clin Med. 2025 Feb 26;14(5):1569. doi: 10.3390/jcm14051569.
4
Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery.通过靶向先天免疫系统和精准药物递送推进炎症性肠病治疗
Int J Mol Sci. 2025 Jan 11;26(2):575. doi: 10.3390/ijms26020575.
5
Health-care resource use and costs associated with inflammatory bowel disease in northwest London: a retrospective linked database study.伦敦西北部炎症性肠病的医疗资源使用情况及成本：一项回顾性关联数据库研究
BMC Gastroenterol. 2024 Dec 30;24(1):480. doi: 10.1186/s12876-024-03559-3.
6
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis.CT-P13 治疗炎症性肠病的疗效：一项系统评价和荟萃分析。
BMC Gastroenterol. 2024 Nov 12;24(1):406. doi: 10.1186/s12876-024-03480-9.
7
Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.接受托法替布治疗的炎症性肠病患者对乌帕替尼的应答。
Dig Dis Sci. 2024 Oct;69(10):3911-3919. doi: 10.1007/s10620-024-08630-3. Epub 2024 Sep 9.
8
Patient preferences for inflammatory bowel disease treatments: protocol development of a global preference survey using a discrete choice experiment.炎症性肠病治疗的患者偏好：使用离散选择实验进行全球偏好调查的方案制定
Front Med (Lausanne). 2024 Aug 14;11:1418874. doi: 10.3389/fmed.2024.1418874. eCollection 2024.
9
Genomic insights into pediatric intestinal inflammatory and eosinophilic disorders using single-cell RNA-sequencing.利用单细胞 RNA 测序技术对小儿肠道炎症性和嗜酸性疾病的基因组进行深入研究。
Front Immunol. 2024 Aug 13;15:1420208. doi: 10.3389/fimmu.2024.1420208. eCollection 2024.
10
Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.荧光标记的维多珠单抗用于可视化炎症性肠病中的药物分布和黏膜靶细胞。
Gut. 2024 Aug 8;73(9):1454-1463. doi: 10.1136/gutjnl-2023-331696.
本文引用的文献
1
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.米拉利珠单抗治疗克罗恩病患者的随机 2 期研究的疗效和安全性。
Gastroenterology. 2022 Feb;162(2):495-508. doi: 10.1053/j.gastro.2021.10.050. Epub 2021 Nov 5.
2
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.抗黏膜地址素细胞黏附分子-1 单克隆抗体 Ontamalimab（SHP647）治疗克罗恩病的长期安全性和疗效：OPERA II 研究。
Inflamm Bowel Dis. 2022 Jul 1;28(7):1034-1044. doi: 10.1093/ibd/izab215.
3
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.一项评估基于孢子的微生物组治疗药物 SER-287 治疗活动性轻中度溃疡性结肠炎的 1b 期安全性研究。
Gastroenterology. 2021 Jan;160(1):115-127.e30. doi: 10.1053/j.gastro.2020.07.048. Epub 2020 Aug 4.
4
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme.用于溃疡性结肠炎的肠道选择性泛 Janus 激酶抑制剂 TD-1473 的研发：一项转化医学计划。
J Crohns Colitis. 2020 Sep 16;14(9):1202-1213. doi: 10.1093/ecco-jcc/jjaa049.
5
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.乌帕替尼在活动性溃疡性结肠炎患者随机试验中的疗效。
Gastroenterology. 2020 Jun;158(8):2139-2149.e14. doi: 10.1053/j.gastro.2020.02.030. Epub 2020 Feb 22.
6
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.乌帕替尼在克罗恩病患者随机试验中的疗效和安全性。
Gastroenterology. 2020 Jun;158(8):2123-2138.e8. doi: 10.1053/j.gastro.2020.01.047. Epub 2020 Feb 8.
7
Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?粪便微生物群移植治疗克罗恩病的疗效：一种新的靶向治疗方法？
Microb Biotechnol. 2020 May;13(3):760-769. doi: 10.1111/1751-7915.13536. Epub 2020 Jan 20.
8
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.在一项针对溃疡性结肠炎患者的 2 期随机试验中，埃特司莫德的疗效和安全性。
Gastroenterology. 2020 Feb;158(3):550-561. doi: 10.1053/j.gastro.2019.10.035. Epub 2019 Nov 9.
9
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.乌司奴单抗诱导和维持溃疡性结肠炎的治疗。
N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.
10
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.在一项溃疡性结肠炎患者的随机 2 期研究中评估米利珠单抗的疗效和安全性。
Gastroenterology. 2020 Feb;158(3):537-549.e10. doi: 10.1053/j.gastro.2019.08.043. Epub 2019 Sep 4.
Zotero 插件